Previous 10 | Next 10 |
-- MyoKardia to Host Conference Call at 8:30 a.m. ET on Monday, June 22, 2020 -- BRISBANE, Calif., June 19, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that data from the company’s Phase 2a multiple-ascending dose study of danicamtiv (formerly MYK-491...
BRISBANE, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that Tassos Gianakakos, Chief Executive Officer, will participate in a fireside chat at the virtual BMO 2020 Prescriptions for Success Healthcare Conference on Tuesday, June 23 rd , 2020 at 10...
Shares of MyoKardia (NASDAQ: MYOK) climbed 62.8% in May, according to data provided by S&P Global Market Intelligence , after the company said its investigational heart drug met primary and secondary endpoints in a phase 3 clinical trial. Image source: Getty Images. Mavacamten is...
MyoKardia (NASDAQ: MYOK) soared 96% this week after reporting its investigational heart drug met primary and all secondary endpoints in a phase 3 clinical trial. The clinical stage biotech company will submit mavacamten for the treatment of obstructive hypertrophic cardiomyopathy (HCM) ...
Myriad Receives the FDA Approval for Testing Ovarian Cancer Myriad Genetics ( MYGN ) announced that the FDA has given green signal to its myChoice CDx test to be used as a companion diagnostic for the identification of advanced ovarian cancer patients. The company stated that the device...
MyoKardia (NASDAQ: MYOK ) has priced its public offering of 5.25M common shares at $105.00/share. More news on: MyoKardia, Inc., Healthcare stocks news, , Stocks on the move, Read more ...
Gainers: Cellect Biotechnology (NASDAQ: APOP ) +77% . More news on: Cellect Biotechnology Ltd., MyoKardia, Inc., Remark Holdings, Inc., Stocks on the move, , Read more ...
MyoKardia (NASDAQ: MYOK) , a clinical-stage biotech, is having a tremendous Monday morning. The drugmaker's shares were up by an eye-popping 65% on sky-high volume as of 9:59 a.m. EDT on Monday. The spark? Ahead of the opening bell, MyoKardia announced that its experimental obstructive...
Cellect Biotechnology (NASDAQ: APOP ) +126% on publication of ApoGraft data ahead of clinical trial. More news on: Cellect Biotechnology Ltd., MyoKardia, Inc., AMC Entertainment Holdings, Inc., Stocks on the move, , Read more ...
MyoKardia (NASDAQ: MYOK ) announces positive results from a Phase 3 clinical trial, EXPLORER-HCM , evaluating lead drug mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), an inherited disorder characterized by abnormal thickening of heart muscle leadi...
News, Short Squeeze, Breakout and More Instantly...
EXPLORER -HCM Cardiac Imaging Data Presented at AHA 2020 Scientific Session with Simultaneous Publication in Circulation Mavacamten T reatment Resulted in Favorable Effect on Cardiac Structure -- Significantly Reduced Hypertrophy in Patien...
ECHO Data from EXPLORER-HCM Show Mavacamten Treatment Improved Cardiac Structure and Mitral Valve Function in Obstructive Hypertrophic Cardiomyopathy Patients Markers of Physical Activity from MAVERICK-HCM Accelerometry Data Correlated with ...
BRISBANE, Calif. and WASHINGTON, Nov. 11, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ: MYOK), and the American College of Cardiology (ACC) announced the establishment of a nationwide registry of hypertrophic cardiomyopathy (HCM), which leverages the ACC’s PINNACLE Cardiovas...